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Abstract
Backgound & Aims—Germline mutations of the APC gene are the pathogenic cause of most
cases of familial adenomatous polyposis (FAP) and a lesser proportion of attenuated FAP (AFAP).
Systematic analysis of APC at the RNA level may provide insight into the pathogenicity of
identified mutations and uncover the molecular basis of FAP/AFAP in families without
identifiable mutations. Here, we analyzed the prevalence of imbalances in the allelic expression of
APC in polyposis families with germline mutations in the gene and without detectable mutations
in APC or and MUTYH.
Methods—Allele-specific expression (ASE) was determined by single nucleotide primer
extension using an exon 11 polymorphism as an allele-specific marker. In total, 52 APC-mutation-
positive (36 families) and 24 APC/MUTYH-mutation-negative (23 families) informative patients
were analyzed. Seventy-six controls were also included.
Results—Of the APC-mutation-positive families, most of those in which the mutation was
located before the last exon of the gene (12 of 14) showed ASE imbalance, which is consistent
with a mechanism of nonsense-mediated decay (NMD). Of the APC/MUTYH mutation-negative
families, two (9%) showed ASE imbalance as a hallmark of the putative pathogenic cause of the
disease. Normal allele expression was restored after treatment of short-term cultured lymphocytes
with puromycin, supporting the NMD hypothesis.
Conclusions—ASE analysis may be an indicator of pathogenicity for some cases of FAP and
AFAP in which APC mutations are not found. ASE might also be useful for prioritizing the order
in which different areas of APC should be tested. Our results underline the importance of RNA-
level studies in molecular diagnosis of FAP.
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BACKGROUND & AIMS
Familial adenomatous polyposis (FAP), an autosomal dominant disease predisposing to
colorectal cancer, is mainly caused by truncating germline mutations in the APC gene
(5q21–22)1. Widespread use of sequencing techniques has led to the identification of an
increased number of missense mutations2, variants with a putative impact on mRNA
splicing3, and cases of somatic and germline mosaicisms4. Exon dose analysis has detected
gross rearrangements in a minority of cases5. Although in a lesser proportion of cases,
attenuated FAP (AFAP) is also associated with APC mutations and with biallelic germline
mutations in the MUTYH gene, showing an autosomal recessive pattern6.
In other cancer predisposition genes such as MSH2, MLH1, BRCA1, BRCA2 and NF1,
studies at the RNA level have shown that mutations causing a premature termination codon
(PTC) usually trigger nonsense-mediated decay (NMD) of the mRNA7-11. This mRNA
surveillance mechanism reduces the abundance of premature stop-codon-harboring mRNA
and of the corresponding truncated proteins. NMD of the affected transcript occurs if the
PTC is located approximately 55 bp upstream of the last intron-exon boundary12. Although
some RNA studies of the APC gene have been published, focused mainly on the presence of
aberrant splicing due to missense, silent or unclassified variants3,13, to date there are no
published studies offering a systematic analysis of the impact of pathogenic APC mutations
at the RNA level.
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The proportion of familial adenomatous polyposis (FAP) families with identifiable APC
mutations has shown a slight increase with the incorporation of new techniques into
diagnostic algorithms. However, a large subset has undetectable pathogenic changes
[designated here as APC(−)/MUTYH(−)]. Small decreases in APC mRNA have been
detected in APC(−)14,15 and APC(−)/MUTYH(−) families16-18. In contrast, high germline
levels of an APC mRNA isoform resulting from an exon 10-15 connection have been
observed in a case of APC(−)/MUTYH(−) AFAP19. Germline imbalances in allele-specific
expression (ASE) of the APC gene have been detected in FAP and AFAP families14, 15, 18,
20, but their potential contribution to diagnostic yield is unknown.
The prevalence of imbalances in APC allelic expression was analyzed in two sets of
polyposis families: APC mutation-positive [designated here as APC(+)] and APC(−)/
MUTYH(−). Here we show that mutations outside exon 15 are associated with a clear allelic
imbalance at the RNA level that is secondary to NMD, and that these imbalances are also
detected in a low proportion of APC(−)/MUTYH(−) families.
PATIENTS AND METHODS
Patients
One hundred and twenty-seven FAP and AFAP families from the Catalan Institute of
Oncology (ICO) and the University of Michigan (UM) were initially tested for germline
APC and MUTYH mutations by comprehensive diagnostic methods (sequencing or SSCP
analysis of all exons and exon-intron boundaries, gross deletion analysis by QMPSF
(Quantitative Multiplex PCR of Short Fluorescent Fragments) and/or MLPA (Multiplex
Ligation-dependent Probe Amplification) and/or Southern blot for the APC gene, presence
of germline epimutations in APC promoter in conjunction with sequencing of the two most
prevalent variants of the MUTYH gene – Y165C and G382D). Mutations were found in 76
families, while the molecular pathogenic cause of the disease remained unknown in 51
families. The mutation detection rates were 83% for FAP and 25% for AFAP.
Individuals from 59 of the families tested heterozygous for the rs2229992 APC coding SNP
in exon 11 of the APC gene and were the informative population of the present study. These
families were divided according to mutational status: (i) 36 APC(+) families (24 classical
FAP, 34 carrier individuals; 12 AFAP, 18 carrier individuals); and (ii) 23 APC(−)/
MUTYH(−) families (5 FAP, 6 individuals; 18 AFAP, 18 individuals).
A total of 76 heterozygous controls were included: 29 non-carriers from APC mutation
families, 6 carriers and 24 non-carriers from MSH2 and MLH1 mutation families, and 17
Ashkenazi Jewish individuals diagnosed with sporadic microsatellite-unstable colorectal
cancer that form part of the Molecular Epidemiology of Colorectal Cancer (MECC) study.
This is a population-based case-control study of incident colorectal cancer (CRC), including
histopathologically confirmed cases from all incident colorectal cancer cases diagnosed in
northern Israel from 31 March 1998 onwards. Informed consent was obtained from all of the
subjects who participated in the study.
Genotyping: SNaPshot analysis of genomic DNA
Peripheral blood lymphocyte DNA was obtained using the FlexiGene DNA kit (Qiagen).
Twenty-five ng of genomic DNA were amplified in a final volume of 25 μL containing 0.13
μmol/L primers, 0.2 mmol/L dNTPs, 2.5 mmol/L MgCl2 and 1.25 U Taq polymerase
(Thermoprime Plus DNA Polymerase; ABgene). After an initial denaturing step, samples
underwent 5 initial cycles (1 min at 94°C, 30 s at 65°C, 30 s at 72°C), 20 cycles (1 min at
94°C, 30 s at 65°C decreasing 0.5°C/cycle, 30 s at 72°C), and 10 final cycles (1 min at 94°C,
30 s at 55°C, 30 s at 72°C). Primers in exon 11 (Forward: 5′-
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GGGACTACAGGCCATTGCA-3′ and reverse: 5′-
CAAGTTTGTCAAAGCCATTCCAGC-3′) were used to amplify the rs2229992 SNP. To
remove unincorporated primers and dNTPs, PCR fragments were purified using illustra™
GFX™ PCR DNA and Gel Band Purification Kit (GE Healthcare). For the single nucleotide
primer extension reaction, primer extension was carried out with the SNaPshot Multiplex
Kit (Applied Biosystems) with 5′-ATTGCAAGTGGACTGTGAAATGTA-3′ according to
manufacturer’s instructions. Briefly, reactions were performed in a total volume of 10 μL
containing 1.5 μL treated PCR product, 4.5 μL SNaPshot Ready Reaction Mix and 0.2
μmol/L extension primer. Primer extension thermocycling conditions consisted of 25 cycles
of 96°C for 10 s, 50°C for 5 s, and 60°C for 30 s. SNaPshot reaction products were treated
with 1 U shrimp alkaline phosphatase (usb) for 60 min at 37°C and then 15 min at 75°C.
Products were run in an ABI Prism 3130 DNA sequencer and analyzed by GeneMapper v4.0
(Applied Biosystems). Heterozygous samples showed a profile with two peaks (black and
red peaks represent C and T alleles, respectively), while only one peak was observed for
homozygous samples.
Measuring ASE: SNaPshot analysis of cDNA
Total RNA was isolated from frozen lymphocytes using Trizol Reagent (Invitrogen)
according to manufacturer’s instructions. Two hundred and fifty ng of RNA were reverse-
transcribed into cDNA using pdN6 primers and MMLV reverse transcriptase (Invitrogen).
To specifically amplify rs2229992 SNP in cDNA, we used the same exon 11 forward primer
as for DNA amplification and a reverse primer targeting the exon 11-12 junction (5′-
ATAGAGCATAGCGTAGCCTTGTTG -3′). PCR reactions were performed in a final
volume of 25 μL containing 2 μL of cDNA, 0.2 μmol/L primers, 0.2 mmol/L dNTPs, 2.5
mmol/L MgCl2 and 1.25 U Taq polymerase (Thermoprime Plus DNA Polymerase;
ABgene). After a denaturing step, 35 cycles of 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C
were performed. The remaining steps were the same as described for genotyping, including
purification, SNaPshot reaction, phosphatase treatment and capillary electrophoresis.
ASE was measured using peak intensities in heterozygous samples. Allelic frequencies were
calculated as freq. C = C/(C+kT) or freq. T = T/(T+k’C), where k and k’ are constants given
by the mean of C/T (k) and T/C (k’) proportions in control samples. These constants were
used to correct for unequal representation of alleles in known control heterozygotes, caused
by differential PCR amplification of alleles, differential efficiencies of ddNTP incorporation
in the extension reaction, unequal emission energies of fluorescent dyes21, or putative
differences in physiological RNA levels due to alternative splicing affecting exons 1, 7, 9,
10A and 14 of the APC gene22-27. ASE values are expressed as the proportion of
frequencies of the two alleles (freq. C:freq. T). Three independent replicates of all
experiments were obtained, and a set of controls was included in every experiment. A
Mann-Whitney test was used to evaluate ASE differences among groups.
To validate the SNaPshot analysis as a quantitative technique, two homozygous samples
representing the two alleles were selected. After reverse transcription, cDNAs were mixed in
different proportions (0:10, 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9:1 and 10:0) and analyzed
in triplicate. As seen in Figure 1, SNaPshot assay of rs2229992 SNP provides a quantitative
measurement of ASE of the APC gene with an analytical sensitivity of at least 10% (Figure
1). To set the cut-off points for equal and unequal expression we used 14 controls from the
ICO subset of samples and obtained a mean value of 1.002±0.055 (Figure 2, A). From these
results we established a conservative range for normal ASE values of 0.836-1.168 with a
confidence of 99% (mean values ± 3·SD). These values were independently validated in an
additional set of 14 controls with a range for normal values of 0.732-1.198 (mean values ±
3·SD), which has been consistently replicated in independent experiments using different
control sets. In the presence of modest inter-experiment variability, a set of control samples
Castellsagué et al. Page 4













was always run in the same experiment. Pyrosequencing was used to confirm the range of
normal ASE values in an independent set of 18 controls. Briefly, germline cDNA and
germline DNA were PCR-amplified using the forward primer
(GAATTATTGCAAGTGGACTGTGAA) and the reverse biotinylated primer
(GCCATTCCAGCATATCGTCTTA) to yield an 83 base-pair amplicon containing
rs2229992. The PCR reaction mixture (25μL) contained 5ng of genomic DNA or 1μL of
cDNA, 2.5μl of 10X PCR buffer (Applied Biosystems), 2μL of 25mM MgCl2 (Applied
Biosystems), 1.25μL of 2.5mM dNTP (New England Biolabs), 0.5μL of each 10μM primer,
and 0.75 U of AmpliTaq Gold DNA polymerase (Applied Biosystems). Cycling conditions
were as follows: initial denaturation at 95°C for 3 min, 50 cycles of 95°C for 34 sec, 60°C
for 45 sec, 72°C for 45 sec, and a final extension at 72°C for 10 min. 5μL of the resulting
PCR product was used for pyrosequencing with the sequencing primer
(GCAAGTGGACTGTGAAAT) according to the standard Qiagen protocol. Normal ASE
values were similar using this technique, ranging from 0.732 to 1.198 (mean values ± 3·SD).
Puromycin analysis
Frozen lymphocytes from a subset of patients and controls were short-cultured in RPMI
1640 + GlutaMAX medium (10% FBS, 1% penicillin-streptomycin) (Gibco) and
phytohemagglutinin (Sigma). After 6-9 days, two subcultures were derived: one was treated
with 250 μg/mL puromycin (Sigma) for 5 hours, while the other was left untreated. RNA
was extracted and ASE calculated as described above.
APC cDNA molecular analysis and promoter analyses
APC cDNA molecular analysis was performed in all APC(−)/MUTYH(−) families showing
ASE imbalance. Six overlapping primer pairs covering all exon-exon boundaries of the APC
gene were designed to test for abnormal cDNA products in these families. Differential
running patterns between test samples and controls were assessed visually using agarose gel
electrophoresis and observed abnormal bands were sequenced. Sequencing of the 1A and 1B
promoter regions of the APC gene was also performed. Finally, APC gene expression levels
were analyzed in all ICO samples by qRT-PCR using a primer pair targeting exons 2 and 3.
The primer sequences and experimental conditions for these analyses are detailed in
Supplementary Table 1.
RESULTS
ASE analysis in APC(+) polyposis families
ASE was assessed in 52 individuals (34 FAP and 18 AFAP) APC(+) from 36 families (24
FAP and 12 AFAP) that tested heterozygous at rs2229992, in parallel with non-carrier
individuals and controls. To categorize ASE, a cut-off range was calculated as described in
Patients and Methods. ASE values <0.836 designated C-allele underexpression and values
>1.168 designated C-allele overexpression, in both cases depicting allelic imbalance. The
average and standard deviation (SD) ASE values for non-carriers (n=24) were 0.964±0.038
(Figure 2, A), with none outside the normal range. Twenty-two families (24 individuals)
showed normal ASE values (range=0.876-1.155). The remaining 14 (39%) showed ASE
imbalances: five families (8 individuals) showed C-allele overexpression
(range=1.214-8.706), eight families (18 individuals) showed C-allele underexpression
(range=0.677-0.830), and one family showed the borderline value of 0.838. Another family,
harboring a deletion from the promoter to exon 4, showed complete loss of T-allele
expression (F-UM-8) and was used as an internal control (Figure 2, A; Table 1).
In accordance with the canonical model of NMD, a strong correlation was observed between
the location of the mutation outside exon 15 (leading to a premature termination codon
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before the last exon of the gene) and the presence of ASE imbalance. Twelve of 14 (86%)
families with mutations outside exon 15 showed abnormal ASE, whereas the proportion
dropped to 2 of 22 (9%) for families with exon 15 mutations (p-value=7.3e-13, obtained
from ASE values) (Table 1; Figure 2, B). Interestingly, the 4 cases that did not fit with the
model showed borderline ASE values. Thus, the ASE values for the two families with
mutations outside exon 15 and with no imbalance (F-UM-2 and F-UM-9) were 1.155 and
1.133 (upper cut-off value 1.168). The two cases with exon 15 mutations and classified as
harboring putative imbalances (F-8 and F-9) showed ASE values of 0.830 and 0.838 (lower
cut-off value 0.836). F-8 harbors a mutation at intron 14 that is predicted to alter intron-exon
processing, leading to a truncated protein at exon 15. F-9 has a recurrent mutation,
p.Gln1062X, that was not associated with ASE in other cases in our series sharing the same
alteration (F-13 and F-22). However, F-9 was classified as putatively abnormal because the
imbalance essentially coincided with the diagnostic threshold value and was confirmed in
cultured lymphocytes (Table 1).
Variations in ASE imbalance depending on the location of the mutation associate with
different APC expression levels. Values of APC germ-line expression in 43 controls were
3.793±2.933. Expression levels in polyposis with exon 15 mutations were similar
(3.647±0.911), while expression levels in polyposis with mutations outside exon 15 were
lower (2.887±0.867; p=0.014).
More than one member (range=2-5) was analyzed in 8 FAP and AFAP families, and all
carriers showed concordant ASE values in 7 of these families (Table 1). In one family (F-2),
two of the three carriers analyzed showed abnormal ASE values (0.823 and 0.717) and the
third carrier showed a normal borderline value (0.853), which probably reflects a degree of
variability between individuals. ASE values were similar among families with the same
mutation. For example, in families F-4 (FAP) and F-23 (AFAP), carriers of the same
splicing mutation (c.834+1G>A), ASE values were similar, although they did not account
for phenotype differences. Allelic imbalance cosegregated with the disease in all cases
analyzed (data not shown).
In nine of the allelic imbalance cases, short-term lymphocyte cultures showed clearer ASE
imbalance than observed in cDNA from peripheral blood lymphocytes. Puromycin treatment
completely reverted imbalance in 8 of the 9 cases. In the remaining case, only partial
reversion was achieved (Table 1). Cultured control lymphocytes showed normal ASE values
that remained unchanged after puromycin treatment (data not shown).
ASE analysis in APC(−)/MUTYH(−) polyposis families
Twenty-three (5 FAP and 18 AFAP) APC(−)/MUTYH(−) families (6 and 18 individuals,
respectively) were heterozygous for the SNP at exon 11 and were subsequently analyzed.
Mean ASE values in controls were 1.001±0.047. Initially, three of the 23 families showed
abnormal APC ASE values (F-29, F-39 and UM-11) (Figure 3 and Table 2). Puromycin
treatment of short-term cultured lymphocytes was performed in the two families from whom
lymphocytes were available (F-29 and F-39) (Table 2). In family F-29, the observed
imbalance was more intense in cultured cells than in PBL and was completely reverted by
puromycin treatment, as expected. In F-39, with an ASE value of 0.819, the imbalance was
no longer observed in cultured lymphocytes. Thus, two of the 23 (9%) APC(−)/MUTYH(−)
families in our series (F-29 and UM-11) harbored ASE imbalance. In F-29, two point
mutations in the promoter region were identified: g.[112043282C>G(+) 112072889C>T].
These changes were not detected in a small set of 9 controls. However, they were not
located in a conserved sequence or a sequence consensus region for transcription factors,
and were not associated with clear changes in APC expression levels as assessed by qRT-
PCR. At the RNA level, the wt transcript coexisted with a second transcript containing a 60
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bp insertion r.[=, 1408_1409ins1408+1315_1408+1369] in UM-11 RNA. These transcripts
were also present in three of five additional samples consisting of either controls or FAP
patients with no ASE imbalance. Interestingly, UM-11 family did not express a transcript
skipping exon 11 that was present in other samples (data not shown). Finally, germline APC
expression levels were lower in APC(−)/MUTYH(−) polyposis families (2.963±1.21) than in
controls (p=0.04) or and APC(+) polyposis families with exon 15 mutations (p=0.01).
DISCUSSION
In this study we adapted the SNuPE (single nucleotide primer extension) methodology to
perform a detailed allele-specific expression analysis of the APC gene in 59 FAP and AFAP
families divided in two groups: those harboring a pathogenic mutation and those with no
identified APC or MUTYH mutation.
In the presence of a detectable deleterious APC gene mutation, ASE imbalance was strongly
associated with mutations located outside exon 15. Conversely, balanced ASE was common
in cases with exon 15 mutations. Both observations fit, albeit imperfectly, with the nuclear
scanning model of NMD in mammals10,12. Our observations are in disagreement with the
findings of Renkonen and colleagues, who reported no ASE imbalance in a small series of 4
families harboring mutations in exons 6-9 of the APC gene, possibly due to differences in
technique or sample processing20. To assess the contribution of NMD to the observed
imbalance, lymphocytes were short-term cultured and treated with puromycin, a known
inhibitor of NMD28. Similarly to previous observations, enhanced allelic expression
imbalance was observed in vitro before puromycin treatment, pointing to higher degradation
of nonsense transcripts associated with culture conditions29. Puromycin treatment
completely restored normal ASE in most of the cases analyzed. However, only partial
reversion was achieved in the case showing the greatest imbalance prior to treatment (F-24,
I-106), and it is unclear whether this can be attributed to the intensity of allelic imbalance,
the limitations of the in vitro assay or other unknown causes.
As has been reported for MSH2, MLH1, BRCA1-2 and NF17-11, the nuclear scanning NMD
model loosely fits with our observations for the APC gene. One of the exceptions is a
mutation at intron 14 that creates a skipping of exon 14 and a PTC at the very beginning of
exon 15 (data not shown) that associates with imbalanced ASE. This may be due to the
special position of the PTC and its sequence context, both of which are factors known to
influence the extent of NMD.
NMD can be considered a modifier of the phenotypic consequences of PTC and has
contributed to our understanding of genotype-phenotype correlations in various genetic
disorders30. In mutations outside exon 15, NMD may promote partial loss-of-function or
haploinsufficiency. Of note, family 24, harboring a frameshift mutation at exon 12, showed
the highest ASE imbalance and an attenuated phenotype. It can be speculated that, in this
case, the mutant allele is degraded leading to a bigger proportion of wt APC homodimers
and a milder phenotype. In mutations causing PTCs in exon 15, absence of NMD activity
may enhance the dominant-negative effect. As such, it is notable that our preliminary
observations indicate lower germline APC expression levels in polyposis with mutations
outside exon 15. An exon-15-mutated allele is not amenable for degradation by NMD, so
this mechanism cannot act as an additional regulatory mechanism. However, no clear
phenotypic correlation between clinical features and location of the mutation was observed
in our series.
Finally, imbalanced ASE was observed in the absence of a detectable mutation in a subset of
APC(−)/MUTYH(−) families assessed by conventional methods. A more detailed analysis of
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cDNA and promoter regions revealed the presence of alterations in APC promoter that may
be functionally relevant in one family, while in the other family a complex pattern of APC
transcripts in the exon 11 region was of unknown significance. We cannot rule out the
possibility that a genetic change deep within an intron may account for the observed ASE
imbalance. In addition, cis-acting regulatory SNPs with an allele-specific effect on APC
might also be responsible for the imbalance31. However, the failure to detect imbalances in
most of the AFAP cases reflects a putative mechanism for their attenuated nature, which
may be more closely related to subtle changes at the RNA level that could lead to delayed
phenotypic expression of symptoms. In fact, germline expression of the APC allele is
slightly lower in these APC(−)/MUTYH(−) and shows no apparent correlation with ASE
imbalance.
Methodological issues should be taken into account in the interpretation of results and have
both theoretical and practical implications. According to our own and others’ results, the
SNaPshot approach is a suitable technique with excellent analytical sensitivity32-35.
Importantly, pyrosequencing (a robust technique) yielded similar normal range values. In
any case, the definition of cut-off values was improved by the inclusion of control set in
every experimental run. The putative clinical relevance of borderline values emphasizes the
importance of the controls. Sample processing is likely to influence the results. Aged blood
has been shown to decrease NMD, thus precluding the detection of loss of allelic imbalance
in the NF1 gene29. The balanced allelic expression of the two samples with mutations
outside exon 15 may be due to differences in the isolation process of peripheral blood
lymphocytes. Finally, the complex pattern of transcripts at exon 11 should be considered, as
it might influence ASE results. Notably, we have identified the expression of transcripts
with skipping of exon 11 in controls (data not shown).
Our results may have clinical implications. Allelic imbalances detected in a small proportion
of APC(−)/MUTYH(−) families point to the presence of a pathogenic event in the APC gene.
Although further studies are needed to elucidate the correlation between allelic imbalance
and the disease in families with no detectable mutation, it could be used as a diagnostic
marker of elusive mutations in the APC gene that might be otherwise only detected by the
more costly conversion approach33 or by next-generation sequencing when implemented in
the routine clinical setting. Based on our results, we propose a new molecular diagnostic
algorithm for polyposis families that undergo APC mutation screening beginning with
analysis of gross rearrangements (Figure 4). In samples with ASE imbalance, sequencing of
exons 1-14 at the cDNA or gDNA level would be followed by analysis of the promoter
region and, possibly, the 3′UTR region. This strategy would have made it unnecessary to
sequence the largest exon of the gene (exon 15, 6574 bp) in approximately 21% of the
families included in the present study (12/58). The pathogenic cause of the disease would
remain unknown if sequencing of the whole coding region of APC and the promoter and
3′UTR regions, and cDNA transcript analyses targeting aberrant skipping or cryptic exons,
revealed no functionally relevant changes. However, a processing protocol for preserving
lymphocytes and RNA would be needed to incorporate this RNA-based assay into routine
screening. Also, the addition of more polymorphisms as allele-specific markers would
improve informativeness and dependability. We do not know whether missense or
unclassified variants from introns 1-14 are associated with ASE imbalance. However,
transcript-level analysis has shown that a significant proportion of these mutations can be
classified as pathogenic and has revealed the presence of PTCs in some cases3.
Taken together, our results reinforce the importance of RNA-level studies not only for a
better understanding of the disease but also for optimizing the molecular diagnostic
algorithm for FAP.
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AFAP attenuated familial adenomatous polyposis
ASE allele-specific expression
FAP familial adenomatous polyposis
FISH fluorescent in-situ hybridization
MLPA multiplex ligation-dependent probe amplification
NMD nonsense-mediated decay
PTC premature termination codon
QMPSF quantitative multiplex PCR of short fluorescent fragments
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Figure 1. SNaPshot analysis of rs2229992 SNP as a quantitative test
Regression analysis of the amplification products of two homozygous control cDNAs mixed
in different proportions and analyzed in triplicate by SNaPshot. Allele frequencies were
calculated by the peak heights: freq. C = C/(C+kT), where the correction factor k is
determined from the mix simulating an actual allele frequency of 0.5 (5:5). Measured allele
frequencies were plotted against the expected values. A near-linear relationship was
observed across all data points (R2 = 0.9983).
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Figure 2. Quantification of ASE in APC(+) polyposis patients
A. Distribution of APC ASE in controls, non-carriers and carriers of a pathogenic APC
mutation from the ICO and UM subsets. ASE values are the proportion between the C and T
allele frequencies of the APC coding SNP rs2229992. Each point represents the mean of the
triplicate measurements, and each replicate was performed for all samples in each subset.
Allelic ratios ranged from 0.646 to 8.706. The normal ASE cut-off range is indicated by
dashed horizontal lines (at 1.168 and 0.836) and determined by control ASE values, as
indicated in Patients and Methods. Three sample electropherograms obtained from the
SNaPshot reaction, and their corresponding ASE values, are also shown. B. Box plots of
ASE values for the location of the mutation in the APC gene. Patients were stratified into
two groups by mutation site (“Outside e15”, mutation located from exons 1-14; and “Inside
e15”, mutation located in exon 15). To give an overview of our results, ASE values are
represented as the proportion of allelic frequencies between the underexpressed and the
overexpressed allele in each sample, independently if whether it is C or T. The interquartile
range includes 50% of the samples and is shown by white boxes. The interdecile range
includes 90% of the patients and is shown as whiskers. Outliers are shown by empty dots.
Mutated groups were compared using the non-parametric Mann-Whitney test.
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Figure 3. Quantification of ASE in APC(−)/MUTYH(−) polyposis patients
Distribution of APC ASE in controls and polyposis patients with no previously identified
mutation. ASE values are the proportion between the C and T allele frequencies of the APC
coding SNP rs2229992. Each point represents the mean of the triplicate measurements, and
each replicate was performed for all samples in each subset. Allelic ratios ranged from 0.756
to 1.284. The normal ASE cut-off range is indicated by dashed horizontal lines (at 1.168 and
0.836).
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Proposed diagnostic algorithm for APC mutation screening including ASE measurement in
polyposis families.
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